by Madaline Spencer | Nov 22, 2024
Ratna Bhavaraju-Sanka, MD, Chief of Neuromuscular Medicine at UT Health San Antonio, discusses Vyvgart’s (efgartigimod alfa) impact on myasthenia gravis (MG) patients. MG is a chronic autoimmune neuromuscular disease characterized by weakness of the...
by Madaline Spencer | Nov 21, 2024
Sabrina Sacconi, MD, PhD, Head of Neuromuscular Disease at Nice University Hospital, discusses recent guidelines for myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. The condition...
by Madaline Spencer | Nov 20, 2024
Emily Milligan, Executive Director of The Barth Syndrome Foundation, discusses the U.S. Food and Drug Administration’s (FDA) recommendation of approval for Barth syndrome treatment, elamipretide. Barth syndrome is a rare metabolic and neuromuscular...
by Madaline Spencer | Nov 19, 2024
Marc Elia, Chairman of the Board of Directors at Invivyd, discusses Pemgarda (pemivibart) for emergency use as a pre-exposure prophylactic therapy for prevention of COVID-19 infection in patients with compromised immune systems. As Mr. Elia explains,...
by Madaline Spencer | Nov 18, 2024
James F. Howard, Jr., MD, The University of North Carolina at Chapel Hill, discusses the interim analysis of the RAISE-XT extension study for myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the...
